Aging
Navigate
Submit an Article
Research Paper|Volume 16, Issue 1|pp 226—245

Aberrant RBMX expression is relevant for cancer prognosis and immunotherapy response

Yilei Sheng1,2, Kunjian Lei1,3,4,5, Chengpeng Sun1,2, Jia Liu6, Zewei Tu1,3,4,5, Xingen Zhu1,3,4,5, Kai Huang1,3,4,5
  • 1Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, P.R. China
  • 2The HuanKui Medical College of Nanchang University, Nanchang 330006, Jiangxi, P.R. China
  • 3Jiangxi Key Laboratory of Neurological Tumors and Cerebrovascular Diseases, Nanchang 330006, Jiangxi, P.R. China
  • 4Institute of Neuroscience, Nanchang University, Nanchang 330006, Jiangxi, P.R. China
  • 5JXHC Key Laboratory of Neurological Medicine, Nanchang 330006, Jiangxi, P.R. China
  • 6Department of Neuroscience, Yale School of Medicine, New Haven, CT 06511, USA
Received: July 5, 2023Accepted: November 3, 2023Published: January 11, 2024
https://doi.org/10.18632/aging.205363

Copyright: © 2024 Sheng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Cancer accounts for the highest rates of morbidity and mortality worldwide. RNA binding motif protein X-linked (RBMX) is a nuclear RNA-binding protein, associated with certain types of cancer by participating in the integration of sister chromatids and a combination of ribonucleoprotein complexes. However, the specific role of RBMX in cancer immunity remains unknown. This study presents the aberrant expression levels, single-cell distributions, effective prognostic roles, immune cell infiltration associations, and immunotherapy responses of RBMX as a biomarker in various types of cancer. Moreover, it validates the aberrant expression of RBMX in clinical cancer samples. Furthermore, we also evaluated the relationships between RBMX expression and myeloid-derived suppressor cells in clinical samples by immunofluorescent staining. The results showed that knockdown of RBMX can impair the proliferation, migration, and invasion of liver cancer cells. Finally, we indicated that RBMX may play an immunoregulatory role in cancer progression, affecting the therapeutic effects of immune checkpoint inhibitors in patients with cancer.